Carregant...
Rebound of medication abortion in Texas following updated mifepristone label
BACKGROUND: In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label. METHODS: Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medi...
Guardat en:
| Publicat a: | Contraception |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852656/ https://ncbi.nlm.nih.gov/pubmed/30684470 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.contraception.2019.01.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|